Evidence map›Paper›PMID 32365460›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Increased Azithromycin Susceptibility of Multidrug-Resistant Gram-Negative Bacteria on RPMI-1640 Agar Assessed by Disk Diffusion Testing.

Milton Meerwein, Andrea Tarnutzer, Michelle Böni, Françoise Van Bambeke, Michael Hombach, Annelies S Zinkernagel

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Bioactivity of Synthesized Trifluoromethyl Thioxanthone Analogues.Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. The proteome of bacterial membrane vesicles inFrontiers in microbiology · 2024
    Article
  9. Article
  10. Article
  11. The Old Yellow Enzyme OfrA FostersFrontiers in microbiology · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Could Azithromycin Be Part ofFrontiers in microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Milton MeerweinDepartment of Infectious Diseases and Hospital Epidemiology, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-8167-192X
Andrea TarnutzerDepartment of Infectious Diseases and Hospital Epidemiology, University of Zurich, 8091 Zurich, Switzerland.
Michelle BöniDepartment of Infectious Diseases and Hospital Epidemiology, University of Zurich, 8091 Zurich, Switzerland.
Françoise Van BambekePharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, B-1200 Brussels, Belgium.ORCID 0000-0002-0052-7991
Michael HombachInstitute of Medical Microbiology, University of Zurich, 8091 Zurich, Switzerland.
Annelies S ZinkernagelDepartment of Infectious Diseases and Hospital Epidemiology, University of Zurich, 8091 Zurich, Switzerland.
University of Zurich · CHUCLouvain · BE

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_146295/1
6 · The paper itself

Abstract

Increasing antibiotic resistances and a lack of new antibiotics render the treatment of Gram-negative bacterial infections increasingly difficult. Therefore, additional approaches are being investigated. Macrolides are not routinely used against Gram-negative bacteria due to lack of evidence of in vitro effectiveness. However, it has been shown that Pseudomonas spp. are susceptible to macrolides in liquid RPMI-1640 and clinical data suggest improvement in patients' outcomes. So far, these findings have been hardly applicable to the clinical setting due to lack of routine low-complexity antimicrobial susceptibility testing (AST) for macrolides. We therefore optimized and compared broth microdilution and disk diffusion AST. Multidrug-resistant Gram-negative bacteria (

Indexed as

azithromycindisk diffusionEnterobacteriaceaeGram-negativeMICmultidrug-resistantPseudomonas aeruginosasusceptibility testing

Identifiers

PMID32365460
PMCPMC7277395
OpenAlexW3022675655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.